Perrigo Reports Q1 Loss of $2.87/Share, Signaling Continued Financial Headwinds
Summary
Perrigo reported a first-quarter loss of $2.87 per share, confirming the significant financial challenges highlighted in its recent 10-K filing. The company's 2025 net loss of $1.43 billion, driven by goodwill impairments, had already set expectations for further impairments in Q1 2026. This reported loss indicates that those anticipated headwinds have materialized, impacting the company's profitability despite the recent sale of its Dermacosmetics business for €305.6 million. Investors will be looking for management commentary on the specific drivers of this loss and any revised outlook for the remainder of the year.
At the time of this announcement, PRGO was trading at $12.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.